-
2023-504880-18-00
9
2018-04-18
Neuroblastoma (NBL)
-
2023-509318-13-00
6
2018-01-15
Multiple indications
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2023-505625-14-00
7
2017-01-31
Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
-
2023-506987-15-00
9
2016-11-17
Metastatic Castration-Resistant Prostate Cancer
-
2024-514791-40-00
9
2016-08-03
pediatric cancer
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
-
2024-518254-16-00
5
2013-03-01
Acute Myeloid Leukemia (Pediatric 0-18 years)
-
2024-517592-20-00
5
2026-05-30
Emergence delirium
-
2023-503684-42-00
4
2026-02-20
Neuroblastoma
-
2025-521970-33-00
5
2025-12-19
Pulmonary Arterial Hypertension (PAH)
-
2025-521249-25-00
7
2025-10-30
MTAP-deleted advanced or metastatic solid tumors
-
2025-521681-10-00
4
2025-10-02
Lung Cancer
-
2024-520050-38-00
5
2025-09-18
Extensive stage small cell lung cancer (ES-SCLC). S
-
2024-516473-72-00
5
2025-07-31
Multifocal Motor Neuropathy
-
2024-518339-12-00
4
2025-07-08
Idiopathic Pulmonary Fibrosis
-
2024-516815-26-00
5
2025-05-30
Chronic rhinosinusitis with nasal polyps
-
2024-513307-13-00
4
2025-05-26
Advanced/metastatic solid tumors including gynecological
cancers (endo
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2024-513968-25-00
5
2025-04-28
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-519628-25-00
6
2025-04-03
Chronic rrhinosinusitis with nasal polyps